Synthetic mistletoe protein meets endpoint in stopping malignant melanoma
Hamburg-based Cytavis Pharma GmbH’s heterologously expressed mistletoe protein Aviscuminum (CY-503) has met the primary endpoint of achieving progression-free survival (PFS) of at least 3 months in 31 patients with inoperable malignant melanoma after failure of prior therapy. The company said the results from the interventional Phase II study also point to efficacy of the twice-weekly, subcutaneously administered heterodimeric protein, which targets the CD75 receptor on cancer cells and kills them with a cytotoxic protein at nanogram doses. One-year survival improved by 45% compared to dacarbazine treatment (30%), with median overall survival of 11 months (Dacarbazine: 6-8 months). The firm, which bought the drug patent from the insolvency mass of Germany’s Viscum AG, is running an efficacy study with more than 200 participants in chemotherapy-refractory metastatic colorectal carcinoma (NCT 00932724).